|
Search
Collections
Benchmarks
Upload document
Product
KT-413
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 clinical trial
3 indications
Indication
Non-Hodgkin Lymphoma
Indication
Diffuse Large B-Cell Lymphoma
Indication
MYD88 Gene Mutation
Clinical trial
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, PK/PD, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL
Status:
, Estimated PCD: 2025-04-01